From Nasdaq:

Ultragenyx Pharmaceutical Inc. (RARE) predicts total revenue of $430-435 million for fiscal year 2023, falling slightly short of analyst estimates. Looking ahead to fiscal year 2024, the company forecasts revenue to reach $500-530 million, in line with analyst expectations. As of December 31, 2023, the company holds approximately $776 million in cash, cash equivalents, and investments, with projected net cash use for 2024 to be less than $400 million. The uses of cash in 2023 included completing construction of a gene therapy manufacturing facility. For more information on earnings news and stocks, visit rttnews.com.



Read more: Ultragenyx Pharma Sees FY23 Total Revenue Below View